Skip to main content

Table 2 Multivariate analysis of recurrence-free survival in patients with stage I-III colon cancers

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

  

Univariate HR

(95% CI)

Multivariate HR

(95% CI)

Age

 

1.015 (0.985-1.047)

1.028 (0.995-1.062)

Sex

Male

1 (referent)

1 (referent)

 

Female

1.438 (0.733-2.819)

1.600 (0.799-3.204)

Stage

Stage I/II

1 (referent)

1 (referent)

 

Stage III

2.303 (1.163-4.561)

2.587 (1.267-5.281)

Differentiation

Well/Moderate

1 (referent)

1 (referent)

 

Poor/Mucinous

1.210 (0.426-3.435)

1.347 (0.415-4.375)

CIMP

CIMP-low/negative

1 (referent)

1 (referent)

 

CIMP-high

0.523 (0.160-1.710)

0.806 (0.207-3.136)

MSI

MSI-low/MSS

1 (referent)

1 (referent)

 

MSI-high

0.394 (0.139-1.118)

0.485 (0.139-1.701)

BRAF mutation

No

1 (referent)

1 (referent)

 

Yes

No recurrence

No recurrence

KRAS mutation

No

1 (referent)

1 (referent)

 

Yes

1.096 (0.542-2.214)

1.185 (0.568-2.471)

MGMT methylation

No

1 (referent)

1 (referent)

 

Yes

0.667 (0.311-1.429)

0.703 (0.304-1.628)

  1. HR hazard ratio, CIMP CpG island methylator phenotype, MSI microsatellite instability, MSS microsatellite stable